98%
921
2 minutes
20
Introduction: Lower urinary tract evaluation in women with pelvic organ prolapse commonly includes measurement of the post-void residual urine volume. Portable bladder scanners may not accurately measure post-void residual urine volume in women with pelvic organ prolapse as the bladder is no longer in its normal anatomical position. In this study we investigated the accuracy of the BladderScan® BVI 9400 to measure post-void residual urine volume in women with prolapse.
Methods: We conducted a prospective observational study of 31 women with pelvic organ prolapse being evaluated in the outpatient setting. Women underwent 3 post-void residual urine volume measurements, including 1) portable bladder scan with prolapse not reduced, 2) portable bladder scan with prolapse reduced and 3) straight catheterization. Student's t-test, Pearson's correlation and Bland-Altman analysis were used to compare the 3 measurements.
Results: There were no differences in absolute errors among the 3 methods of measurement (all p >0.05). All 3 measurements were strongly correlated (all r >0.85 and all p <0.001). The bladder scan measurements obtained during prolapse reduction did not appear to agree more with the catheterized volume than the bladder scan measurements obtained when prolapse was not reduced. Bladder scan error was not related to obesity (p=0.46) or prior hysterectomy (p=0.81).
Conclusions: Pelvic organ prolapse did not affect post-void residual urine volume measurement error using a portable bladder scanner. Thus, it may be unnecessary to reduce stage 2-3 pelvic organ prolapse before obtaining a post-void residual urine volume measurement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.urpr.2017.01.004 | DOI Listing |
Cureus
August 2025
Agriculture Extension, Muhammad Nawaz Shareef University of Agriculture, Multan, PAK.
Background: Bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH) is a common urological condition in aging men, often requiring surgical intervention for symptom relief.
Objective: To evaluate the therapeutic efficacy and complication profile of monopolar transurethral resection of the prostate (TURP) in patients with BOO.
Methodology: This descriptive observational study was conducted at the Department of Urology, Hayatabad Medical Complex, Peshawar, and Akhtar Saeed Trust Hospital, Lahore, from August 2022 to July 2024.
Turk J Surg
September 2025
Department of Pediatric Surgery, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Objective: This study aimed to evaluate the functional status of the urethra using uroflowmetry before surgery, as well as three and six months postoperatively in cases of distal hypospadias.
Material And Methods: Thirty-nine consecutive patients who underwent surgery for distal hypospadias (hypospadias group) between 2016 and 2019 were prospectively included as part of this study. The control group consisted of 40 patients with a normal urethra who underwent surgery due to conditions other than hypospadias (phimosis, undescended testis, hernia).
World J Urol
September 2025
Department of Urology, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei, 10002, Taiwan (R.O.C.).
Purpose: To characterize the learning process by comparing the clinical outcomes and learning curves of prostatic urethral lift (PUL) performed by experienced versus naïve urologists.
Methods: Consecutive patients treated with PUL at a tertiary center by an experienced urologist with > 100 PUL cases or by naïve urologists with no prior PUL experience were included in this study. Perioperative parameters, functional outcomes, complications, and retreatment rates were compared.
Investig Clin Urol
September 2025
Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Purpose: This study aimed to compare the clinical outcomes of Aquablation and Holmium Laser Enucleation of the Prostate (HoLEP) for the treatment of benign prostatic hyperplasia (BPH), with emphasis on functional improvement, ejaculatory preservation, and perioperative safety.
Materials And Methods: We retrospectively analyzed data from January 2023 to March 2024, excluding patients with follow-up shorter than 3 months. Propensity score matching was performed using age, prostate volume, and preoperative prostate-specific antigen (PSA).
Cent European J Urol
May 2025
Faculty of Medicine, Muslim University of Indonesia, Makassar, Indonesia.
Introduction: Over the last few years, trends in managing benign prostatic hyperplasia (BPH) have improved, advancing from reliance on surgery to satisfactory medical therapies. However, the efficacy and safety of combination therapies, including silodosin and tadalafil, are not well established compared to monotherapy for treating lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO).
Material And Methods: A systematic search was conducted in PubMed, ScienceDirect, Cochrane Library, and Scopus up to April 1, 2024.